Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 730357 long-term extension in plaque psoriasis
NCT03835481Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of bevurogant in plaque psoriasis, sponsored by Boehringer Ingelheim. Started Mar 2019; status: terminated.
02
Drugs
bevurogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03835481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835481.